electroCore (ECOR)
(Delayed Data from NSDQ)
$5.91 USD
-0.29 (-4.68%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
electroCore, Inc. [ECOR]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong Start Bodes Well for FY2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong Revenue Growth Expected to Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong 2023 Indicates Start of Inflection; New PT $15.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ECOR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
Growth in All Business Segments Bodes Well for 2024; PT Up To $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
All Cylinders Firing; New PT $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
2023 Strong Start Bodes Well for Full Year; New PT $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Guidance Underscores Management Confidence in Strategy; New PT of $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Exits 2022 on a Strong Note; New Revenue Streams in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Growth Momentum Maintained in 2Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Starting 2022 on Strong Footing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Teijin Partnership to Pave the Way into Japanese Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong 2021 Paves Way For Growth in 2022; Adjust PT to $2.75; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S